Maria Weiner1, Su Mein Goh2, Aladdin J Mohammad3, Zdenka Hruskova4, Anisha Tanna5, Annette Bruchfeld6, Daina Selga7, Zdenka Chocova4, Kerstin Westman7, Per Eriksson8, Charles D Pusey5, Vladimir Tesar4, Alan D Salama2, Mårten Segelmark9. 1. Departments of Nephrology and Medical and Health Sciences and maria.weiner@liu.se. 2. University College London Centre for Nephrology, Royal Free Hospital, London, United Kingdom; 3. Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden; Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom; 4. Department of Nephrology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic; 5. Department of Medicine, Imperial College London, London, United Kingdom; 6. Department of Renal Medicine, Karolinska University Hospital, and Department of Clinical Sciences, Intervention, and Technology, Karolinska Institute, Stockholm, Sweden; and. 7. Department of Nephrology, Lund University, Skåne University Hospital, Lund and Malmö, Sweden. 8. Rheumatology and Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; 9. Departments of Nephrology and Medical and Health Sciences and.
Abstract
BACKGROUND AND OBJECTIVES: ANCA-associated vasculitis is commonly found in elderly patients, but there are few data concerning outcome and treatment in the highest age groups. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Consecutive patients (N=151) presenting between 1997 and 2009 were retrospectively included from local registries in six centers in Sweden, the United Kingdom, and the Czech Republic if diagnosed with microscopic polyangiitis or granulomatosis with polyangiitis at age ≥75 years during the study period. Patients were followed until 2 years from diagnosis or death. Data on survival and renal function were analyzed with respect to age, sex, ANCA specificity, renal function, C-reactive protein, comorbidities, and Birmingham Vasculitis Activity Score at diagnosis as well as treatment during the first month. RESULTS: Median follow-up was 730 days (interquartile range, 244-730). Overall 1-year survival was 71.5% and 2-year survival was 64.6%. Older age, higher creatinine, and lower Birmingham Vasculitis Activity Score were associated with higher mortality in multivariable analysis. Patients who were not treated with standard immunosuppressive therapy had significantly worse survival. Renal survival was 74.8% at 1 year. No new cases of ESRD occurred during the second year. High creatinine at diagnosis was the only significant predictor of renal survival in multivariable analysis. CONCLUSIONS: ANCA-associated vasculitis is a disease with substantial mortality and morbidity among elderly patients. This study showed a better prognosis for those who received immunosuppressive treatment and those who were diagnosed before having developed advanced renal insufficiency.
BACKGROUND AND OBJECTIVES: ANCA-associated vasculitis is commonly found in elderly patients, but there are few data concerning outcome and treatment in the highest age groups. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Consecutive patients (N=151) presenting between 1997 and 2009 were retrospectively included from local registries in six centers in Sweden, the United Kingdom, and the Czech Republic if diagnosed with microscopic polyangiitis or granulomatosis with polyangiitis at age ≥75 years during the study period. Patients were followed until 2 years from diagnosis or death. Data on survival and renal function were analyzed with respect to age, sex, ANCA specificity, renal function, C-reactive protein, comorbidities, and Birmingham Vasculitis Activity Score at diagnosis as well as treatment during the first month. RESULTS: Median follow-up was 730 days (interquartile range, 244-730). Overall 1-year survival was 71.5% and 2-year survival was 64.6%. Older age, higher creatinine, and lower Birmingham Vasculitis Activity Score were associated with higher mortality in multivariable analysis. Patients who were not treated with standard immunosuppressive therapy had significantly worse survival. Renal survival was 74.8% at 1 year. No new cases of ESRD occurred during the second year. High creatinine at diagnosis was the only significant predictor of renal survival in multivariable analysis. CONCLUSIONS: ANCA-associated vasculitis is a disease with substantial mortality and morbidity among elderly patients. This study showed a better prognosis for those who received immunosuppressive treatment and those who were diagnosed before having developed advanced renal insufficiency.
Authors: Francisco Silva; Philip Seo; Darrell R Schroeder; John H Stone; Peter A Merkel; Gary S Hoffman; Robert Spiera; Jodi K Sebastian; John C Davis; E William St Clair; Nancy B Allen; W Joseph McCune; Steven R Ytterberg; Ulrich Specks Journal: Arthritis Rheum Date: 2011-08
Authors: Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne Journal: Ann Rheum Dis Date: 2011-11-29 Impact factor: 19.103
Authors: Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne Journal: Am J Kidney Dis Date: 2003-04 Impact factor: 8.860
Authors: Alfred Mahr; Sandrine Katsahian; Hugo Varet; Loïc Guillevin; E Christiaan Hagen; Peter Höglund; Peter A Merkel; Christian Pagnoux; Niels Rasmussen; Kerstin Westman; David R W Jayne Journal: Ann Rheum Dis Date: 2012-09-08 Impact factor: 19.103
Authors: Paul A Lyons; Tim F Rayner; Sapna Trivedi; Julia U Holle; Richard A Watts; David R W Jayne; Bo Baslund; Paul Brenchley; Annette Bruchfeld; Afzal N Chaudhry; Jan Willem Cohen Tervaert; Panos Deloukas; Conleth Feighery; Wolfgang L Gross; Loic Guillevin; Iva Gunnarsson; Lorraine Harper; Zdenka Hrušková; Mark A Little; Davide Martorana; Thomas Neumann; Sophie Ohlsson; Sandosh Padmanabhan; Charles D Pusey; Alan D Salama; Jan-Stephan F Sanders; Caroline O Savage; Mårten Segelmark; Coen A Stegeman; Vladimir Tesař; Augusto Vaglio; Stefan Wieczorek; Benjamin Wilde; Jochen Zwerina; Andrew J Rees; David G Clayton; Kenneth G C Smith Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: Sirada Panupattanapong; Dustin L Stwalley; Andrew J White; Margaret A Olsen; Anthony R French; Mary E Hartman Journal: Arthritis Rheumatol Date: 2018-12 Impact factor: 10.995
Authors: Bertha M Córdova-Sánchez; Juan M Mejía-Vilet; Luis E Morales-Buenrostro; Georgina Loyola-Rodríguez; Norma O Uribe-Uribe; Ricardo Correa-Rotter Journal: Clin Rheumatol Date: 2016-02-06 Impact factor: 2.980
Authors: Claudius Speer; Christine Altenmüller-Walther; Jan Splitthoff; Christian Nusshag; Florian Kälble; Paula Reichel; Christian Morath; Martin Zeier; Raoul Bergner; Matthias Schaier Journal: Medicine (Baltimore) Date: 2021-07-23 Impact factor: 1.817